Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 858542, 13 pages
http://dx.doi.org/10.1155/2015/858542
Review Article

“New” Antigenic Targets and Methodological Approaches for Refining Laboratory Diagnosis of Antiphospholipid Syndrome

1Dipartimento di Medicina Sperimentale, Sapienza Università di Roma, Viale Regina Elena 324, 00161 Roma, Italy
2Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, Viale del Policlinico 155, 00161 Roma, Italy

Received 15 December 2014; Revised 27 February 2015; Accepted 3 March 2015

Academic Editor: Eiji Matsuura

Copyright © 2015 Roberta Misasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. R. V. Hughes, “The anticardiolipin syndrome,” Clinical and Experimental Rheumatology, vol. 3, no. 4, pp. 285–286, 1985. View at Google Scholar · View at Scopus
  2. G. R. Hughes, N. N. Harris, and A. E. Gharavi, “The anticardiolipin syndrome,” The Journal of Rheumatology, vol. 13, no. 3, pp. 486–489, 1986. View at Google Scholar · View at Scopus
  3. R. A. Asherson, M. A. Khamashta, and J. Ordi-Ros, “The primary antiphospolipid syndrome: major clinical and serological features,” Medicine, vol. 68, no. 6, pp. 366–374, 1989. View at Google Scholar
  4. W. Lim, “Antiphospholipid syndrome,” Hematology, vol. 2013, no. 1, pp. 675–680, 2013. View at Publisher · View at Google Scholar
  5. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. E. J. Favaloro and R. C. W. Wong, “Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of chellenges and recent guidelines,” Pathology, vol. 46, no. 6, pp. 481–495, 2014. View at Publisher · View at Google Scholar
  7. P. G. de Groot and R. T. Urbanus, “The future of antiphospholipid antibody testing,” Seminars in Thrombosis and Hemostasis, vol. 38, no. 4, pp. 412–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Otomo, T. Atsumi, O. Amengual et al., “Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events,” Arthritis & Rheumatism, vol. 64, no. 2, pp. 504–512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Ç. Agar, G. M. A. Van Os, M. Mörgelin et al., “Beta2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome,” Blood, vol. 116, no. 8, pp. 1336–1343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Shoenfeld, G. Twig, U. Katz, and Y. Sherer, “Autoantibody explosion in antiphospholipid syndrome,” Journal of Autoimmunity, vol. 30, no. 1-2, pp. 74–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L. Bertolaccini, “Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review,” Thrombosis and Haemostasis, vol. 111, no. 2, pp. 354–364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Ortona, A. Capozzi, T. Colasanti et al., “Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome,” Blood, vol. 116, no. 16, pp. 2960–2967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Sorice, T. Griggi, A. Circella et al., “Protein S antibodies in acquired protein S deficiencies,” Blood, vol. 83, no. 8, pp. 2383–2384, 1994. View at Google Scholar · View at Scopus
  14. J. Arachchillage, M. Efthymiou, I. J. Mackie, A. S. Lawrie, S. J. Machin, and H. Cohen, “Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome,” Journal of Thrombosis and Haemostasis, vol. 12, no. 11, pp. 1801–1809, 2014. View at Publisher · View at Google Scholar
  15. J. Kaburaki, M. Kuwana, M. Yamamoto, S. Kawai, and Y. Ikeda, “Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus,” American Journal of Hematology, vol. 54, no. 3, pp. 209–213, 1997. View at Google Scholar
  16. V. Salle, J. C. Mazière, A. Smail et al., “Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome,” Journal of Clinical Immunology, vol. 28, no. 4, pp. 291–297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Kobayashi, E. Stang, K. S. Fang, P. de Moerloose, R. G. Parton, and J. Gruenberg, “A lipid associated with the antiphospholipid syndrome regulates endosome structure and function,” Nature, vol. 392, no. 6672, pp. 193–197, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Alessandri, M. Bombardieri, L. di Prospero et al., “Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus,” Clinical and Experimental Immunology, vol. 140, no. 1, pp. 173–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Merten, S. Motamedy, S. Ramamurthy, F. C. Arnett, and P. Thiagarajan, “Sulfatides targets for antiphospholipid antibodies,” Circulation, vol. 108, no. 17, pp. 2082–2087, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. H. P. McNeil, R. J. Simpson, C. N. Chesterman, and S. A. Krilis, “Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H),” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 11, pp. 4120–4124, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. P. G. de Groot and J. C. M. Meijers, “β2-glycoprotein I: evolution, structure and function,” Journal of Thrombosis and Haemostasis, vol. 9, no. 7, pp. 1275–1284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Sorice, A. Longo, A. Capozzi et al., “Anti-β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts,” Arthritis & Rheumatism, vol. 56, no. 8, pp. 2687–2697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Colasanti, C. Alessandri, A. Capozzi et al., “Autoantibodies specific to a peptide of β2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes,” Blood, vol. 120, no. 16, pp. 3360–3370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Lopez, K. Kobayashi, J. T. Merrill, E. Matsuura, and L. R. Lopez, “IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome,” Clinical and Developmental Immunology, vol. 10, no. 2–4, pp. 203–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. C. W. Wong, E. J. Favaloro, S. Adelstein et al., “Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting,” Pathology, vol. 40, no. 1, pp. 58–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. R. T. Urbanus, B. Siegerink, M. Roest, F. R. Rosendaal, P. G. de Groot, and A. Algra, “Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study,” The Lancet Neurology, vol. 8, no. 11, pp. 998–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Neville, J. Rauch, J. Kassis et al., “Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort,” Thrombosis and Haemostasis, vol. 101, no. 1, pp. 100–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Barbhaiya and D. Erkan, “Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?” Current Rheumatology Reports, vol. 13, no. 1, pp. 59–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Koike, K. Ichikawa, T. Atsumi, H. Kasahara, and E. Matsuura, “β2-Glycoprotein I-anti-β2-glycoprotein I interaction,” Journal of Autoimmunity, vol. 15, no. 2, pp. 97–100, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. G. M. Iverson, E. Matsuura, E. J. Victoria, K. A. Cockerill, and M. D. Linnik, “The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA,” Journal of Autoimmunity, vol. 18, no. 4, pp. 289–297, 2002. View at Google Scholar
  31. G. M. Iverson, E. J. Victoria, and D. M. Marquis, “Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15542–15546, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. B. de Laat and P. G. de Groot, “Autoantibodies directed against domain i of beta2-glycoprotein I,” Current Rheumatology Reports, vol. 13, no. 1, pp. 70–76, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. B. de Laat, V. Pengo, I. Pabinger et al., “The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study,” Journal of Thrombosis and Haemostasis, vol. 7, no. 11, pp. 1767–1773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Agnon-Levin, L. Seguro, C. Rosario et al., “Anti-2-GPI-DI antibodies are a marker of APS severity,” Arthritis & Rheumatology, vol. 65, supplement 10, p. 1, 2013. View at Google Scholar
  35. Y. Ioannou, C. Pericleous, I. Giles, D. S. Latchman, D. A. Isenberg, and A. Rahman, “Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2) glycoprotein I: mutation studies including residues R39 to R43,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 280–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Agostinis, P. Durigutto, D. Sblattero et al., “A human monoclonal antibody against domain I of 2-glycoprotein I prevents clotting and fetal loss induced by polyclonal anti-phospholipid antibodies in animal models,” Arthritis & Rheumatology, vol. 65, p. 5245, 2013. View at Google Scholar
  37. C. Nalli, L. Andreoli, M. Motta et al., “Fine specificity of anti-β2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1,” Reumatismo, vol. 63, no. 2, pp. 91–96, 2011. View at Google Scholar · View at Scopus
  38. M. Mahler, G. L. Norman, P. L. Meroni, and M. Khamashta, “Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome,” Autoimmunity Reviews, vol. 12, no. 2, pp. 313–317, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. S. S. Pierangeli, X. W. Liu, J. H. Barker, G. Anderson, and E. N. Harris, “Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome,” Thrombosis and Haemostasis, vol. 74, no. 5, pp. 1361–1367, 1995. View at Google Scholar · View at Scopus
  40. A. Danowski, T. S. Kickler, and M. Petri, “Anti-β 2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus,” The Journal of Rheumatology, vol. 33, no. 9, pp. 1775–1779, 2006. View at Google Scholar · View at Scopus
  41. M. L. Bertolaccini, O. Amengual, T. Atsumi et al., “'Non-criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010,” Lupus, vol. 20, no. 2, pp. 191–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Ruiz-García, M. Serrano, J. Ángel Martínez-Flores et al., “Isolated IgA anti-β2 Glycoprotein i antibodies in patients with clinical criteria for antiphospholipid syndrome,” Journal of Immunology Research, vol. 2014, Article ID 704395, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. H. L. Staub, G. L. Norman, T. Crowther et al., “Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia,” Arquivos de Neuro-Psiquiatria, vol. 61, no. 3, pp. 757–763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. J. D. Oosting, R. H. W. M. Derksen, I. W. G. Bobbink, T. M. Hackeng, B. N. Bouma, and P. G. de Groot, “Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?” Blood, vol. 81, no. 10, pp. 2618–2625, 1993. View at Google Scholar · View at Scopus
  45. M. Torricelli, L. Sabatini, P. Florio et al., “Levels of antibodies against protein C and protein S in pregnancy and in preeclampsia,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 22, no. 11, pp. 993–999, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Sorice, P. Arcieri, T. Griggi et al., “Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency,” Thrombosis and Haemostasis, vol. 75, no. 4, pp. 555–559, 1996. View at Google Scholar · View at Scopus
  47. R. Forastiero, M. Martinuzzo, G. Pombo et al., “A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis,” Journal of Thrombosis and Haemostasis, vol. 3, no. 6, pp. 1231–1238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Bizzaro, A. Ghirardello, S. Zampieri et al., “Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study,” Journal of Thrombosis and Haemostasis, vol. 5, no. 6, pp. 1158–1164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. M. L. Bertolaccini, T. Atsumi, T. Koike, G. R. V. Hughes, and M. A. Khamashta, “Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus,” Thrombosis and Haemostasis, vol. 93, no. 2, pp. 289–297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Conti, A. Capozzi, S. Truglia et al., “The mosaic of ‘seronegative’ antiphospholipid syndrome,” Journal of Immunology Research, vol. 2014, Article ID 389601, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Boilard, S. G. Bourgoin, C. Bernatchez, and M. E. Surette, “Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2,” Blood, vol. 102, no. 8, pp. 2901–2909, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Mor-Vaknin, A. Punturieri, K. Sitwala, and D. M. Markovitz, “Vimentin is secreted by activated macrophages,” Nature Cell Biology, vol. 5, no. 1, pp. 59–63, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. T. J. Podor, D. Singh, P. Chindemi et al., “Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface,” The Journal of Biological Chemistry, vol. 277, no. 9, pp. 7529–7539, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. B. Xu, R. M. DeWaal, N. Mor-Vaknin, C. Hibbard, D. M. Markovitz, and M. L. Kahn, “The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature,” Molecular and Cellular Biology, vol. 24, no. 20, pp. 9198–9206, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Thébault, D. Gilbert, M. Hubert et al., “Orderly pattern of development of the autoantibody response in (New Zealand White × BXSB)F1 lupus mice: characterization of target antigens and antigen spreading by two-dimensional gel electrophoresis and mass spectrometry,” Journal of Immunology, vol. 169, no. 7, pp. 4046–4053, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Romay-Penabad, M. G. Montiel-Manzano, T. Shilagard et al., “Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo,” Blood, vol. 114, no. 14, pp. 3074–3083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. K. L. Allen, F. V. Fonseca, V. Betapudi, B. Willard, J. Zhang, and K. R. McCrae, “A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies,” Blood, vol. 119, no. 3, pp. 884–893, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Cañas, L. Simonin, F. Couturaud, and Y. Renaudineau, “Annexin A2 autoantibodies in thrombosis and autoimmune diseases,” Thrombosis Research, vol. 135, no. 2, pp. 226–230, 2015. View at Publisher · View at Google Scholar
  59. G. Cesarman-Maus, N. P. Ríos-Luna, A. B. Deora et al., “Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome,” Blood, vol. 107, no. 11, pp. 4375–4382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. M. L. Bertolaccini, O. Amengual, L. Andreoli et al., “14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends,” Autoimmunity Reviews, vol. 13, no. 9, pp. 917–930, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. D. W. Branch, R. Silver, S. Pierangeli, I. van Leeuwen, and E. N. Harris, “Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome,” Obstetrics & Gynecology, vol. 89, no. 4, pp. 549–555, 1997. View at Publisher · View at Google Scholar · View at Scopus
  62. M. L. Bertolaccini, B. Roch, O. Amengual, T. Atsumi, M. A. Khamashta, and G. R. V. Hughes, “Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome,” British Journal of Rheumatology, vol. 37, no. 11, pp. 1229–1232, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Fialová, L. Mikulíková, I. Matouš-Malbohan, O. Benešová, and A. Zwinger, “Prevalence of various antiphospholipid antibodies in pregnant women,” Physiological Research, vol. 49, no. 3, pp. 299–305, 2000. View at Google Scholar · View at Scopus
  64. R. D. Franklin and W. H. Kutteh, “Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population,” Human Reproduction, vol. 17, no. 11, pp. 2981–2985, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Katsuragawa, H. Kanzaki, T. Inoue, T. Hirano, T. Mori, and N. S. Rote, “Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion,” Biology of Reproduction, vol. 56, no. 1, pp. 50–58, 1997. View at Publisher · View at Google Scholar · View at Scopus
  66. A. E. Gharavi, E. N. Harris, R. A. Asherson, and G. R. V. Hughes, “Anticardiolipin antibodies: isotype distribution and phospholipid specificity,” Annals of the Rheumatic Diseases, vol. 46, no. 1, pp. 1–6, 1987. View at Publisher · View at Google Scholar · View at Scopus
  67. A. E. Tebo, T. D. Jaskowski, A. R. Phansalkar, C. M. Litwin, D. W. Branch, and H. R. Hill, “Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome,” The American Journal of Clinical Pathology, vol. 129, no. 6, pp. 870–875, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. A. E. Tebo, T. D. Jaskowski, H. R. Hill, and D. W. Branch, “Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss,” Clinical and Experimental Immunology, vol. 154, no. 3, pp. 332–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. J.-C. Gris, I. Quéré, M. Sanmarco et al., “Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes obstetricians and Haematologists Study—NOHA,” Thrombosis and Haemostasis, vol. 84, no. 2, pp. 228–236, 2000. View at Google Scholar · View at Scopus
  70. T. Sugi, H. Matsubayashi, A. Inomo, L. Dan, and T. Makino, “Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss,” Journal of Obstetrics and Gynaecology Research, vol. 30, no. 4, pp. 326–332, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Sanmarco, S. Gayet, M.-C. Alessi et al., “Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis—a multicenter study with the participation of the European Forum on antiphospholipid antibodies,” Thrombosis and Haemostasis, vol. 97, no. 6, pp. 949–954, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Sanmarco, “ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results,” Journal of Immunological Methods, vol. 358, no. 1-2, pp. 9–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Gruenberg and T. E. Kreis, “Membranes and sorting,” Current Opinion in Cell Biology, vol. 7, no. 4, pp. 519–522, 1995. View at Publisher · View at Google Scholar · View at Scopus
  74. B. Galve-de Rochemonteix, T. Kobayashi, C. Rosnoblet et al., “Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 2, pp. 563–574, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Valesini and C. Alessandri, “New facet of antiphospholipid antibodies,” Annals of the New York Academy of Sciences, vol. 1051, pp. 487–497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Sorice, D. Ferro, R. Misasi et al., “Evidence for anticoagulant activity and β2-GPI accumulation in late endosomes of endothelial cells induced by anti-LBPA antibodies,” Thrombosis and Haemostasis, vol. 87, no. 4, pp. 735–741, 2002. View at Google Scholar · View at Scopus
  77. S. Olivieri, A. Ruffatti, A. Bontadi et al., “Clinical value of antibodies to lysobisphosphatidic acid in patients with primary antiphospholipid sindrome,” Reumatismo, vol. 62, no. 2, pp. 107–112, 2010. View at Google Scholar · View at Scopus
  78. M. L. Bertolaccini, G. R. V. Hughes, and M. A. Khamashta, “Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins,” Clinical Laboratory, vol. 50, no. 11-12, pp. 653–665, 2004. View at Google Scholar · View at Scopus
  79. F. H. Passam and S. A. Krilis, “Laboratory tests for the antiphospholipid syndrome: current concepts,” Pathology, vol. 36, no. 2, pp. 129–138, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Oku, T. Atsumi, O. Amengual, and T. Koike, “Antiprothrombin antibody testing: detection and clinical utility,” Seminars in Thrombosis and Hemostasis, vol. 34, no. 4, pp. 335–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Devreese and M. F. Hoylaerts, “Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome,” European Journal of Haematology, vol. 83, no. 1, pp. 1–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Persijn, A. S. Decavele, S. Schouwers, and K. Devreese, “Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome,” Thrombosis Research, vol. 128, no. 6, pp. 565–569, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. F. van Hoecke, L. Persijn, A.-S. Decavele, and K. Devreese, “Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome,” International Journal of Laboratory Hematology, vol. 34, no. 6, pp. 630–640, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Capozzi, E. Lococo, M. Grasso et al., “Detection of antiphospholipid antibodies by automated chemiluminescence assay,” Journal of Immunological Methods, vol. 379, no. 1-2, pp. 48–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. F. Capuano, V. Grasso, L. Belforte et al., “Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues,” Annals of the New York Academy of Sciences, vol. 1109, no. 1, pp. 493–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. P. de Moerloose, G. Reber, J. Musial, and J. Arnout, “Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome,” Journal of Thrombosis and Haemostasis, vol. 8, no. 7, pp. 1540–1546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Noubouossie, J. Valsamis, F. Corazza, L. Rozen, F. Debaugnies, and A. Demulder, “An automated chemiluminescence immunoassay may detect mostly relevant IgG anticardiolipin antibodies according to revised Sydney criteria.,” Acta clinica Belgica, vol. 67, no. 3, pp. 184–189, 2012. View at Google Scholar · View at Scopus
  88. K. Conrad, H. Schneider, T. Ziemssen et al., “A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies,” Annals of the New York Academy of Sciences, vol. 1109, pp. 256–264, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Conrad, D. Roggenbuck, A. Ittenson, D. Reinhold, T. Buettner, and M. W. Laass, “A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency,” Clinical Chemistry and Laboratory Medicine, vol. 50, no. 2, pp. 337–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Egerer, D. Roggenbuck, T. Büttner et al., “Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay,” Arthritis Research and Therapy, vol. 13, no. 4, article R118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. R. R. Forastiero, M. E. Martinuzzo, and L. O. Carreras, “Binding properties of antibodies to prothrombin and β2-glycoprotein I (β2-GPI) assayed by ELISA and dot blot,” Clinical & Experimental Immunology, vol. 118, no. 3, pp. 480–486, 1999. View at Publisher · View at Google Scholar · View at Scopus
  92. E. M. Bevers, R. F. A. Zwaal, and G. M. Willems, “The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin,” Clinical Immunology, vol. 112, no. 2, pp. 150–160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Metzger, P. von Landenberg, M. Kehrel, A. Buhl, K. J. Lackner, and P. B. Luppa, “Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies,” Clinical Chemistry, vol. 53, no. 6, pp. 1137–1143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. K. Conrad, D. Roggenbuck, D. Reinhold, and T. Dörner, “Profiling of rheumatoid arthritis associated autoantibodies,” Autoimmunity Reviews, vol. 9, no. 6, pp. 431–435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. P. von Landenberg, J. Schölmerich, J. von Kempis, and K. J. Lackner, “The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis. A retrospective study from a single center,” Immunobiology, vol. 207, no. 1, pp. 65–71, 2003. View at Google Scholar · View at Scopus
  96. V. Pengo, A. Biasiolo, C. Pegoraro, U. Cucchini, F. Noventa, and S. Iliceto, “Antibody profiles for the diagnosis of antiphospholipid syndrome,” Thrombosis and Haemostasis, vol. 93, no. 6, pp. 1147–1152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Sorice, T. Griggi, A. Circella et al., “Detection of antiphospholipid antibodies by immunostaining on thin layer chromatography plates,” Journal of Immunological Methods, vol. 173, no. 1, pp. 49–54, 1994. View at Publisher · View at Google Scholar · View at Scopus
  98. F. Conti, C. Alessandri, F. R. Spinelli et al., “TLC immunostaining for detection of ‘antiphospholipid’ antibodies,” Methods in Molecular Biology, vol. 1134, pp. 95–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Sorice, V. Pittoni, T. Griggi et al., “Specificity of anti-phospholipid antibodies in infectious mononucleosis: a role for anti-cofactor protein antibodies,” Clinical and Experimental Immunology, vol. 120, no. 2, pp. 301–306, 2000. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Alessandri, M. Sorice, M. Bombardieri et al., “Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis,” Arthritis Research and Therapy, vol. 8, article R180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Conti, C. Alessandri, M. Sorice et al., “Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome,” Clinical & Experimental Immunology, vol. 167, no. 3, pp. 429–437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Nayfe, I. Uthman, J. Aoun, E. S. Aldin, M. Merashli, and M. A. Khamashta, “Seronegative antiphospholipid syndrome,” Rheumatology, vol. 52, no. 8, Article ID ket126, pp. 1358–1367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Alessandri, F. Conti, P. Conigliaro, R. Mancini, L. Massaro, and G. Valesini, “Seronegative autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 1173, pp. 52–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. G. R. V. Hughes and M. A. Khamashta, “Seronegative antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 62, no. 12, p. 1127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Cervera, F. Conti, A. Doria, L. Iaccarino, and G. Valesini, “Does seronegative antiphospholipid syndrome really exist?” Autoimmunity Reviews, vol. 11, no. 8, pp. 581–584, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. M. L. Bertolaccini, S. Gomez, J. F. P. Pareja et al., “Antiphospholipid antibody tests: spreading the net,” Annals of the Rheumatic Diseases, vol. 64, no. 11, pp. 1639–1643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. P. L. Meroni, C. B. Chighizola, F. Rovelli, and M. Gerosa, “Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers,” Arthritis Research and Therapy, vol. 16, no. 2, article 209, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. B. de Laat, K. Mertens, and P. G. de Groot, “Mechanisms of disease: antiphospholipid antibodies—from clinical association to pathologic mechanism,” Nature Clinical Practice Rheumatology, vol. 4, no. 4, pp. 192–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Galli, “Interpretation and recommended testing for antiphospholipid antibodies,” Seminars in Thrombosis and Hemostasis, vol. 38, no. 4, pp. 348–352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. V. Pengo, A. Banzato, E. Bison, A. Bracco, G. Denas, and A. Ruffatti, “What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?” Seminars in Thrombosis and Hemostasis, vol. 38, no. 4, pp. 322–327, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. V. Pengo, A. Ruffatti, T. Del Ross et al., “Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile,” Journal of Thrombosis and Haemostasis, vol. 11, no. 8, pp. 1527–1531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. V. Pengo, A. Ruffatti, C. Legnani et al., “Clinical course of high-risk patients diagnosed with antiphospholipid syndrome,” Journal of Thrombosis and Haemostasis, vol. 8, no. 2, pp. 237–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. E. J. Favaloro, “Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants,” International Journal of Laboratory Hematology, vol. 35, no. 3, pp. 269–274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Ruffatti, A. Calligaro, A. Hoxha et al., “Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome,” Arthritis Care and Research, vol. 62, no. 3, pp. 302–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L. Bertolaccini, “GAPSS: the global anti-phospholipid syndrome score,” Rheumatology, vol. 52, no. 8, pp. 1397–1403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. E. N. Harris, J. K. H. Chan, R. A. Asherson, V. R. Aber, A. E. Gharavi, and G. R. Hughes, “Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test,” Archives of Internal Medicine, vol. 146, no. 11, pp. 2153–2156, 1986. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Galli, L. Ruggeri, and T. Barbui, “Differential effects of anti-β2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C,” Blood, vol. 91, no. 6, pp. 1999–2004, 1998. View at Google Scholar · View at Scopus
  118. L. Cousins, C. Pericleous, M. Khamashta et al., “Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 74, no. 1, pp. 317–319, 2014. View at Publisher · View at Google Scholar
  119. M. Samarkos, R. A. Asherson, and S. Loizou, “The clinical significance of IgA antiphospholipid antibodies,” The Journal of Rheumatology, vol. 28, no. 4, pp. 694–697, 2001. View at Google Scholar · View at Scopus
  120. A. Satoh, K. Suzuki, E. Takayama et al., “Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus,” The Journal of Rheumatology, vol. 26, no. 8, pp. 1715–1720, 1999. View at Google Scholar · View at Scopus